Journal article icon

Journal article

Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate

Abstract:
Neuroimaging studies in schizophrenia have linked elevated glutamate metabolite levels to non-remission following antipsychotic treatment, and also indicate that antipsychotics can reduce glutamate metabolite levels. However, the relationship between symptomatic reduction and change in glutamate during initial antipsychotic treatment is unclear. Here we report proton magnetic resonance spectroscopy (1H-MRS) measurements of Glx and glutamate in the anterior cingulate cortex (ACC) and thalamus in patients with first episode psychosis (n = 23) at clinical presentation, and after 6 weeks and 9 months of treatment with antipsychotic medication. At 9 months, patients were classified into Remission (n = 12) and Non-Remission (n = 11) subgroups. Healthy volunteers (n = 15) were scanned at the same three time-points. In the thalamus, Glx varied over time according to remission status (P = 0.020). This reflected an increase in Glx between 6 weeks and 9 months in the Non-Remission subgroup that was not evident in the Remission subgroup (P = 0.031). In addition, the change in Glx in the thalamus over the 9 months of treatment was positively correlated with the change in the severity of Positive and Negative Syndrome Scale (PANSS) positive, total and general symptoms (P<0.05). There were no significant effects of group or time on glutamate metabolites in the ACC, and no differences between either patient subgroup and healthy volunteers. These data suggest that the nature of the response to antipsychotic medication may be related to the pattern of changes in glutamatergic metabolite levels over the course of treatment. Specifically, longitudinal reductions in thalamic Glx levels following antipsychotic treatment are associated with symptomatic improvement.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1038/s41537-019-0080-1

Authors

More by this author
Role:
Author
ORCID:
0000-0002-5716-4941
More by this author
Role:
Author
ORCID:
0000-0002-7923-5480
More by this author
Role:
Author
ORCID:
0000-0002-3878-3659


Publisher:
Springer Science and Business Media LLC
Journal:
NPJ schizophrenia More from this journal
Volume:
5
Issue:
1
Pages:
12-12
Publication date:
2019-08-01
DOI:
EISSN:
2334-265X
ISSN:
2334-265X


Language:
English
Keywords:
Pubs id:
2359354
Local pid:
pubs:2359354
Source identifiers:
W2965094820
Deposit date:
2026-01-15
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP